Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT.

Prostate cancer and prostatic diseases - 1 Jun 2020

Ahmed Mahbubl, Goh Chee, Saunders Edward, Cieza-Borrella Clara, Kote-Jarai Zsofia, Schumacher Fredrick R, Eeles Ros

Abstract excerpt

BACKGROUND: The development of prostate cancer can be influenced by genetic and environmental factors. Numerous germline SNPs influence prostate cancer susceptibility. The functional pathways in which these SNPs increase prostate cancer susceptibility are unknown. Finasteride is currently not being used routinely as a chemoprevention agent but the long term outcomes of the PCPT trial are awaited. The outcomes of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to Follow-Up Studies

Share to Germ-Line Mutation

Share to Prognosis

Share to Prostatic Neoplasms

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 31776447
DOI: 10.1038/s41391-019-0181-y
PMCID: PMC7237354

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT.PMID 31776447Read ↗

Polygenic Risk Scores in Prostate Cancer Risk Assessment and Screening.Semantic proximity Read ↗

Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.Semantic proximity Read ↗

Prostate cancer risk prediction using a polygenic risk score.Semantic proximity Read ↗

Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.Semantic proximity Read ↗

A genetic risk score to guide age-specific, personalized prostate cancer screeningSemantic proximity Read ↗

Assessment of a Polygenic Risk Score in Screening for Prostate CancerSemantic proximity Read ↗

A genetic-based approach to personalized prostate cancer screening and treatment.Semantic proximity Read ↗

SNPs associated with prostate cancer risk and prognosis.Semantic proximity Read ↗

Family History of Prostate and Breast Cancer Integrated with a Polygenic Risk Score Identifies Men at Highest Risk of Dying from Prostate Cancer before Age 75 Years.Semantic proximity Read ↗

Predictive value of polygenic risk score for prostate cancer incidence and prognosis in the Han ChineseSemantic proximity Read ↗

Predictive value of polygenic risk score for prostate cancer incidence and prognosis in the Han Chinese.Semantic proximity Read ↗

Clinical consequences of a genetic predisposition toward higher benign prostate-specific antigen levels.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.